Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1.
High glucose (HG) has been shown to induce insulin resistance in both type 1 and type 2 diabetes. However, the molecular mechanism behind this phenomenon is unknown. Insulin receptor substrate (IRS) proteins are the key signaling molecules that mediate insulin's intracellular actions. Genetic and biological studies have shown that reductions in IRS1 and/or IRS2 protein levels are associated with insulin resistance. In this study we have shown that proteasome degradation of IRS1, but not of IRS2, is involved in HG-induced insulin resistance in Chinese hamster ovary (CHO) cells as well as in primary hepatocytes. To further investigate the molecular mechanism by which HG induces insulin resistance, we examined various molecular candidates with respect to their involvement in the reduction in IRS1 protein levels. In contrast to the insulin-induced degradation of IRS1, HG-induced degradation of IRS1 did not require IR signaling or phosphatidylinositol 3-kinase/Akt activity. We have identified glycogen synthase kinase 3beta (GSK3 beta or GSK3B as listed in the MGI Database) as a kinase required for HG-induced serine(332) phosphorylation, ubiquitination, and degradation of IRS1. Overexpression of IRS1 with mutation of serine(332) to alanine partially prevents HG-induced IRS1 degradation. Furthermore, overexpression of constitutively active GSK3 beta was sufficient to induce IRS1 degradation. Our data reveal the molecular mechanism of HG-induced insulin resistance, and support the notion that activation of GSK3 beta contributes to the induction of insulin resistance via phosphorylation of IRS1, triggering the ubiquitination and degradation of IRS1.
Leng
Sanhua
S
The Section of Endocrinology, The University of Chicago, 900 East 57th Street, Chicago, Illinois 60637, USA.
Zhang
Wenshuo
W
Zheng
Yanbin
Y
Liberman
Ziva
Z
Rhodes
Christopher J
CJ
Eldar-Finkelman
Hagit
H
Sun
Xiao Jian
XJ
D000818:Animals; D016466:CHO Cells / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D005947:Glucose / Q000378:metabolism*; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta; D022781:Hepatocytes / Q000378:metabolism; D015151:Immunoblotting; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism*; D007333:Insulin Resistance; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D015398:Signal Transduction; D054875:Ubiquitination
D055504:Insulin Receptor Substrate Proteins; D019869:Phosphatidylinositol 3-Kinases; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D046988:Proteasome Endopeptidase Complex; D005947:Glucose
J Biol Chem. 2000 Jul 7;275(27):20880-6
10764799
J Biol Chem. 2005 Feb 11;280(6):4422-8
15574412
Vitam Horm. 2009;80:351-87
19251044
Cell Metab. 2007 Oct;6(4):329-37
17908561
Nature. 2001 Nov 29;414(6863):514-21
11734846
Diabetes. 1997 Oct;46(10):1572-8
9313752
Biochem Biophys Res Commun. 1994 May 30;201(1):71-7
8198614
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9660-4
9275179
Mol Cell Biol. 2007 Jun;27(12):4328-39
17371841
J Biol Chem. 2006 Dec 22;281(51):39071-80
17068339
Diabetes. 1999 Jul;48(7):1359-64
10389839
Nature. 1995 Dec 21-28;378(6559):785-9
8524413
Diabetes. 2000 Jun;49(6):981-91
10866051
Nature. 2000 Jul 6;406(6791):86-90
10894547
BMC Mol Biol. 2004 Sep 06;5:15
15350195
Diabetologia. 2004 Oct;47(10):1661-7
15480539
EMBO J. 1990 Aug;9(8):2431-8
2164470
J Clin Invest. 2005 Mar;115(3):718-27
15711641
Can J Physiol Pharmacol. 2006 Jul;84(7):725-37
16998536
Diabetes. 2000 Feb;49(2):263-71
10868943
Arch Pharm Res. 2004 Apr;27(4):361-70
15180298
J Clin Invest. 1995 Jul;96(1):132-40
7615783
Am J Physiol Endocrinol Metab. 2008 Jun;294(6):E1169-77
18430969
J Cell Biol. 1969 Dec;43(3):506-20
4900611
Diabetes. 1994 Aug;43(8):1066-84
8039601
FEBS Lett. 2006 Apr 3;580(8):1932-40
16530186
J Clin Invest. 1999 Apr;103(7):931-43
10194465
Nature. 1994 Nov 10;372(6502):186-90
7526222
Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S49-57
17478001
J Biol Chem. 1994 Feb 4;269(5):3381-6
7508912
Biochem J. 2007 Dec 15;408(3):297-315
17850214
Diabetes. 1999 Aug;48(8):1662-6
10426388
J Am Soc Nephrol. 2006 Oct;17(10):2812-20
16943306
Mol Cell Biol. 1993 Dec;13(12):7418-28
7504175
Eur J Endocrinol. 2003 Jan;148(1):157-67
12534369
Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E497-506
11832350
FEBS Lett. 1997 Oct 27;416(3):307-11
9373175
Biochem J. 2001 Oct 1;359(Pt 1):1-16
11563964
J Biol Chem. 2000 Jul 21;275(29):22558-62
10811632
J Diabetes Complications. 2002 Jan-Feb;16(1):69-71
11872371
Diabetes. 2002 Jul;51(7):2190-8
12086949
Mol Cell Biol. 2002 Feb;22(4):1016-26
11809794
Metabolism. 2004 Oct;53(10):1322-30
15375789
Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96
16493415
Ann N Y Acad Sci. 1999 Nov 18;892:187-203
10842663
J Clin Invest. 1996 Feb 1;97(3):613-20
8609215
Am J Physiol Endocrinol Metab. 2000 Jan;278(1):E103-12
10644543
Diabetes. 1982 Sep;31(9):795-801
6761214
Mol Cell Biol. 2000 Mar;20(5):1489-96
10669726
Am J Physiol Endocrinol Metab. 2003 Dec;285(6):E1267-72
12954597
J Biol Chem. 2002 Nov 1;277(44):42394-8
12228220
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4171-5
9108124
Diabetes. 1992 May;41(5):571-80
1568526
Cell. 1997 Feb 21;88(4):561-72
9038347
Diabetologia. 1994 Oct;37(10):1025-35
7851681
Nature. 1991 Jul 4;352(6330):73-7
1648180
J Investig Med. 2000 Jul;48(4):251-8
10916283
J Clin Invest. 1992 Nov;90(5):1839-49
1331176
Cardiovasc Diabetol. 2005 Oct 05;4:16
16207378